ESPE Abstracts (2018) 89 P-P1-153

Testing the Performance of a Preexisting Growth Prediction Model in a Cohort of Prepubertal Patients Born Small for Gestational Age (SGA) Receiving GH Treatment in PATRO Children

Christof Landa, Roland Pfäffleb, Karl Otfried Schwabc, Heide Sommerd & Carl Joachim Partsche


aClinic for Paediatric Endocrinology, Gauting, Germany; bDepartment of Paediatric Endocrinology, University Children’s Hospital, Leipzig, Germany; cDepartment of Paediatric Endocrinology, University Children’s Hospital, Freiburg, Germany; dHexal AG, Holzkirchen, Germany; eDepartment of Paediatric Endocrinology, Endokrinologikum, Hamburg, Germany


Aim and background: Growth hormone (GH) treatment of short children born SGA and its effects on growth varies greatly between treated individuals. In the present study we tested the performance of a preexisting growth prediction model (Ranke et al.; JCE&M 2003 pp. 125–131) to estimate 1st-year height velocity (HV) in a german subcohort of prepubertal children born SGA treated with GH (Omnitrope).

Methods: 190 treatment-naïve prepubertal children born SGA (72 girls) were enrolled within the international post authorisation safety study PATRO children. The model was validated by comparing predicted and observed HV in the first year of treatment with Omnitrope.

Results: Baseline characteristics at start of GH treatment and predicted vs. observed 1-year growth rate as well as the index of responsiveness are given in the table. Mean predicted and observed 1-year HV were similar and the mean index of responsiveness was close to zero.

Table 1
ParameterMeanS.D.Median
Age at GH start6.582.146.00
Height SDS baseline−3.110.79−2.95
GH dose at start (mg/kg/day)0.0320.0060.033
1st-year Δ-height SDS0.7310.300.74
1st-year observed HV (cm/yr)8.581.548.80
1st-year predicted HV (cm/yr)8.610.738.78
Index of Responsiveness (IoR)−0.0241.089−0.020

Conclusions: Our results indicate accurate performance of the growth prediction model. It may therefore be used for growth monitoring and individualization of GH therapy in children treated with the biosimilar Omnitrope.

Article tools

My recent searches

No recent searches.